India‑based Syngene International completed site upgrades, opening a dedicated peptide laboratory in Bengaluru and deploying advanced automation across DMPK and Direct‑to‑Biology (D2B) workflows. The company said the facility supports peptides up to 800 mmol, runs six automated synthesizers in parallel, and integrates purification and QC to shorten timelines. Syngene reported a reduction in DMPK turnaround times from five days to three, a 30% improvement in cost efficiency, and tripled sample capacity through automation. The D2B platform is positioned to accelerate hit‑to‑lead cycles by combining miniaturized synthesis and high‑throughput screening. Syngene framed the investment as a strategic move to capture rising peptide and conjugate workloads from pharma and biotech partners.